1,7-phenanthroline has been researched along with Tuberculosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanwar, AJ; Khuller, GK; Sharma, A; Sharma, S | 1 |
| Basaraba, RJ; Bossmann, SH; Harber, GJ; Kutsch, O; Michalek, SM; Niederweis, M; Shrestha, TB; Speer, A; Wolschendorf, F | 1 |
2 other study(ies) available for 1,7-phenanthroline and Tuberculosis
| Article | Year |
|---|---|
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
Topics: Amidohydrolases; Animals; Antibiotics, Antitubercular; Dipeptides; Drug Synergism; Drug Therapy, Combination; Hydroxamic Acids; Hydroxylamine; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Phenanthrolines; Protease Inhibitors; Rifampin; Tuberculosis | 2009 |
Copper-boosting compounds: a novel concept for antimycobacterial drug discovery.
Topics: Antitubercular Agents; Copper; Drug Design; High-Throughput Screening Assays; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenanthrolines; Trace Elements; Tuberculosis; Virulence Factors | 2013 |